GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Common Stock

Cellectis (LTS:0WA2) Common Stock : €5.62 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cellectis Common Stock?

Cellectis's quarterly common stock declined from Jun. 2024 (€5.48 Mil) to Sep. 2024 (€5.32 Mil) but then increased from Sep. 2024 (€5.32 Mil) to Dec. 2024 (€5.62 Mil).

Cellectis's annual common stock increased from Dec. 2022 (€2.79 Mil) to Dec. 2023 (€4.00 Mil) and increased from Dec. 2023 (€4.00 Mil) to Dec. 2024 (€5.62 Mil).


Cellectis Common Stock Historical Data

The historical data trend for Cellectis's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Common Stock Chart

Cellectis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.29 2.61 2.79 4.00 5.62

Cellectis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.03 5.48 5.32 5.62

Cellectis Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Cellectis Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines